- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Annual Issues
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Reviewers Acknowledgment
- Submit a Manuscript
- Subscription Information
- Table of Contents
Oxidative Medicine and Cellular Longevity
Volume 2013 (2013), Article ID 919313, 9 pages
Nrf2 Is Crucial to Graft Survival in a Rodent Model of Heart Transplantation
1Department of Pharmacology and Toxicology, The University of Arizona, Tucson, AZ 85721, USA
2Department of Cardiothoracic Surgery, Southwest Hospital, Third Military Medical University, Chongqing 400038, China
3Department of Pathology, School of Medicine, Northwestern University, Chicago, IL 60611, USA
4Department of Pathology, The University of Arizona, Tucson, AZ 85724, USA
Received 26 November 2012; Accepted 15 January 2013
Academic Editor: Jingbo Pi
Copyright © 2013 Wei Wu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- E. L. Donovan, J. M. McCord, D. J. Reuland, B. F. Miller, and K. L. Hamilton, “Phytochemical activation of Nrf2 protects human coronary artery endothelial cells against an oxidative challenge,” Oxidative Medicine and Cellular Longevity, vol. 2012, Article ID 132931, 9 pages, 2012.
- M. Zhang, C. An, Y. Gao, R. K. Leak, J. Chen, and F. Zhang, “Emerging roles of Nrf2 and phase II antioxidant enzymes in neuroprotection,” Progress in Neurobiology, vol. 100, no. 1, pp. 30–47, 2013.
- H. Zheng, S. A. Whitman, W. Wu et al., “Therapeutic potential of Nrf2 activators in streptozotocin-induced diabetic nephropathy,” Diabetes, vol. 60, no. 11, pp. 3055–3066, 2011.
- G. E. Mann, B. Bonacasa, T. Ishii, and R. C. Siow, “Targeting the redox sensitive Nrf2-Keap1 defense pathway in cardiovascular disease: protection afforded by dietary isoflavones,” Current Opinion in Pharmacology, vol. 9, no. 2, pp. 139–145, 2009.
- M. K. Kwak and T. W. Kensler, “Targeting NRF2 signaling for cancer chemoprevention,” Toxicology and Applied Pharmacology, vol. 244, no. 1, pp. 66–76, 2010.
- C. J. Oh, J. Y. Kim, A. K. Min et al., “Sulforaphane attenuates hepatic fibrosis via NF-E2-related factor 2-mediated inhibition of transforming growth factor-β/Smad signaling,” Free Radical Biology and Medicine, vol. 52, no. 3, pp. 671–682, 2012.
- J. Jiang, Z. C. Mo, K. Yin et al., “Epigallocatechin-3-gallate prevents TNF-α-induced NF-κB activation thereby upregulating ABCA1 via the Nrf2/Keap1 pathway in macrophage foam cells,” International Journal of Molecular Medicine, vol. 29, no. 5, pp. 946–956, 2012.
- X. D. Shen, B. Ke, H. Ji et al., “Disruption of type-I IFN pathway ameliorates preservation damage in mouse orthotopic liver transplantation via HO-1 dependent mechanism,” The American Journal of Transplantation, vol. 12, no. 7, pp. 1730–1739, 2012.
- M. Mohammadzadeh, R. Halabian, A. Gharehbaghian et al., “Nrf-2 overexpression in mesenchymal stem cells reduces oxidative stress-induced apoptosis and cytotoxicity,” Cell Stress and Chaperones, vol. 17, no. 5, pp. 553–565, 2012.
- N. Gorbunov, G. Petrovski, N. Gurusamy, D. Ray, D. H. Kim, and D. K. Das, “Regeneration of infarcted myocardium with resveratrol-modified cardiac stem cells,” Journal of Cellular and Molecular Medicine, vol. 16, no. 1, pp. 174–184, 2012.
- P. Moi, K. Chan, I. Asunis, A. Cao, and Y. W. Kan, “Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the β-globin locus control region,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 21, pp. 9926–9930, 1994.
- I. Heron, “A technique for accessory cervical heart transplantation in rabbits and rats,” Acta pathologica et Microbiologica Scandinavica A, vol. 79, no. 4, pp. 366–372, 1971.
- S. Stewart, G. L. Winters, M. C. Fishbein et al., “Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection,” Journal of Heart and Lung Transplantation, vol. 24, no. 11, pp. 1710–1720, 2005.
- S. Fleige, V. Walf, S. Huch, C. Prgomet, J. Sehm, and M. W. Pfaffl, “Comparison of relative mRNA quantification models and the impact of RNA integrity in quantitative real-time RT-PCR,” Biotechnology Letters, vol. 28, no. 19, pp. 1601–1613, 2006.
- S. A. Bustin, V. Benes, J. A. Garson et al., “The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments,” Clinical Chemistry, vol. 55, no. 4, pp. 611–622, 2009.
- A. Sánchez–Fueyo and T. B. Strom, “Immunologic basis of graft rejection and tolerance following transplantation of liver or other solid organs,” Gastroenterology, vol. 140, no. 1, pp. 51.e2–64.e2, 2011.
- H. X. A. Yeang, J. M. Hamdam, L. M. A. Al-Huseini et al., “Loss of transcription factor nuclear factor-erythroid 2 (NF-E2) p45-related factor-2 (Nrf2) leads to dysregulation of immune functions, redox homeostasis,and intracellular signaling in dendritic cells,” The Journal of Biological Chemistry, vol. 287, no. 13, pp. 10556–10564, 2012.
- T. Rangasamy, M. A. Williams, S. Bauer et al., “Nuclear erythroid 2 p45-related factor 2 inhibits the maturation of murine dendritic cells by ragweed extract,” The American Journal of Respiratory Cell and Molecular Biology, vol. 43, no. 3, pp. 276–285, 2010.
- H. J. Kim, B. Barajas, M. Wang, and A. E. Nel, “Nrf2 activation by sulforaphane restores the age-related decrease of TH1 immunity: role of dendritic cells,” Journal of Allergy and Clinical Immunology, vol. 121, no. 5, pp. 1255.e7–1261.e7, 2008.
- J. M. Lee, K. Chan, Y. W. Kan, and J. A. Johnson, “Targeted disruption of Nrf2 causes regenerative immune-mediated hemolytic anemia,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 26, pp. 9751–9756, 2004.
- J. Li, T. D. Stein, and J. A. Johnson, “Genetic dissection of systemic autoimmune disease in Nrf2-deficient mice,” Physiological Genomics, vol. 18, pp. 261–272, 2004.
- S. A. Rushworth, X. L. Chen, N. Mackman, R. M. Ogborne, and M. A. O'Connell, “Lipopolysaccharide-induced heme oxygenase-1 expression in human monocytic cells is mediated via Nrf2 and protein kinase C,” The Journal of Immunology, vol. 175, no. 7, pp. 4408–4415, 2005.
- S. A. Rushworth, D. J. MacEwan, and M. A. O'Connell, “Lipopolysaccharide-induced expression of NAD(P)H:quinone oxidoreductase 1 and heme oxygenase-1 protects against excessive inflammatory responses in human monocytes,” The Journal of Immunology, vol. 181, no. 10, pp. 6730–6737, 2008.
- R. K. Thimmulappa, R. J. Fuchs, D. Malhotra et al., “Preclinical evaluation of targeting the Nrf2 pathway by triterpenoids (CDDO-Im and CDDO-Me) for protection from LPS-induced inflammatory response and reactive oxygen species in human peripheral blood mononuclear cells and neutrophils,” Antioxidants and Redox Signaling, vol. 9, no. 11, pp. 1963–1970, 2007.
- G. Chalasani, Q. Li, B. T. Konieczny et al., “The allograft defines the type of rejection (acute versus chronic) in the face of an established effector immune response,” The Journal of Immunology, vol. 172, no. 12, pp. 7813–7820, 2004.